- Medicinal cannabis company Little Green Pharma (LGP) has welcomed the Therapeutic Goods Administration’s (TGA) regulatory changes to cannabidiol (CBD)
- The TGA has down-scheduled some CBD products and also increased the daily maximum dosage limit
- This decision means from early next year registered CBD products can dispense over-the-counter without the need for a prescription
- Commenting on the TGA’s decision, Little Green Pharma Managing Director Fleta Solomon said the change should benefit the entire industry
- LGP has congratulated the TGA for the change, stating the down-scheduling will make medicinal cannabis more widely available across Australia
- Shares in Little Green Pharma have ended the day down a slight 0.83 percent trading at 59.5 cents each
